

# Epidemiology and antimicrobial resistance patterns of urinary tract infection: insights and strategies from a 5-year serial cross-sectional study in Vietnam

Anh Tram Que, Anh Dao Tran<sup>ID</sup>, Thi Hong Nhung Trang, Thi Nhu Le Tran<sup>ID</sup>,  
Ngoc-Niem Bui<sup>ID</sup> and Chih-Ho Lai<sup>ID</sup>

## Abstract

**Background:** Urinary tract infection (UTI) is one of the most common bacterial infections in clinical practice. Given the rapid increase in antimicrobial resistance and the scarcity of new antibiotics, along with the absence of individual antibiogram testing in some countries, there is an urgent need for robust surveillance systems.

**Objective:** This study aimed to provide evidence for the surveillance of resistance, a crucial component in developing national UTI treatment guidelines and guiding empirical therapy decisions.

**Design:** This study utilized a retrospective, serial cross-sectional design.

**Methods:** Antimicrobial surveillance was conducted using data collected from January 1, 2017 to December 31, 2021. A total of 2595 patients with UTIs were recruited for this study. From these patients, 2004 bacterial isolates were identified and subjected to epidemiological and antibiotic resistance analyses.

**Results:** *Escherichia coli* (*E. coli*, 42.7%), *Pseudomonas aeruginosa* (*P. aeruginosa*, 11.9%), and *Klebsiella pneumoniae* (*K. pneumoniae*, 10.9%) were identified as the predominant causes of UTIs. *E. coli* isolates demonstrated a high level of sensitivity (80%–90%) to carbapenems (imipenem, ertapenem, and meropenem), aminoglycosides (amikacin), piperacillin/tazobactam, cefoperazone/sulbactam, and fosfomycin. The antibiotic resistance rates of *K. pneumoniae* strains consistently exceeded 50%, except for amikacin, ertapenem, imipenem, meropenem, and fosfomycin. Notably, all *K. pneumoniae* strains isolated from patients with UTIs were resistant to ampicillin. During the coronavirus disease pandemic, the *E. coli* and *K. pneumoniae* isolates exhibited reduced antibiotic resistance compared to the pre-pandemic period. The resistance rate of *P. aeruginosa* isolates remained consistently high (60%–70%).

**Conclusion:** Amikacin, ertapenem, imipenem, meropenem, and fosfomycin are promising treatment options for enterobacterial UTIs. However, their efficacy against *P. aeruginosa* is limited. This study revealed alarmingly high rates of primary etiological pathogen resistance to commonly prescribed empirical therapies for UTIs. These findings provide crucial data for optimizing national guidelines and implementing personalized treatment strategies to enhance the effectiveness of UTI treatments.

**Keywords:** antibiotic resistance, empirical antibiotics, urinary tract infections, Vietnam

Received: 26 May 2024; revised manuscript accepted: 7 January 2025.

*Ther Adv Infect Dis*

2025, Vol. 12: 1–11

DOI: 10.1177/  
20499361251315346

© The Author(s), 2025.  
Article reuse guidelines:  
sagepub.com/journals-  
permissions

Correspondence to:

**Ngoc-Niem Bui**  
Faculty of Medicine, Can  
Tho University of Medicine  
and Pharmacy, Can Tho  
900000, Vietnam

Graduate Institute of  
Biomedical Sciences,  
College of Medicine, Chang  
Gung University, Taoyuan  
33302, Taiwan  
[bnniem@ctump.edu.vn](mailto:bnniem@ctump.edu.vn)

**Chih-Ho Lai**  
Department of Medical  
Research, School of  
Medicine, China Medical  
University and Hospital,  
Taichung 404328, Taiwan

Department of Nursing,  
Asia University, Taichung  
413305, Taiwan

Department of Pediatrics,  
Molecular Infectious  
Disease Research Center,  
Chang Gung Memorial  
Hospital at Linkou,  
Taoyuan 333423, Taiwan

Research Center for  
Emerging Viral Infections,  
Chang Gung University,  
Taoyuan 333323, Taiwan

Department of  
Microbiology and  
Immunology, Chang Gung  
University, Taoyuan, 33302,  
Taiwan

Center for the Molecular  
and Clinical Immunology,  
Institute of Immunology  
and Translational  
Medicine, Chang Gung  
University, Taoyuan  
333323, Taiwan  
[chlai@mail.cgu.edu.tw](mailto:chlai@mail.cgu.edu.tw)

**Anh Tram Que**  
**Anh Dao Tran**  
Department of Medical  
Laboratory, Infectious  
Disease Research Center,  
Nghe An Friendship  
General Hospital, Vinh,  
Nghe An, Vietnam

**Thi Hong Nhung Trang**  
College of Medicine, Tra Vinh University, Tra Vinh, Vietnam

**Thi Nhu Le Tran**  
Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam

## Introduction

Urinary tract infections (UTIs) are among the most common bacterial infections in various parts of the urinary tract, including the kidneys, ureters, bladder, and urethra.<sup>1,2</sup> Although men and women of all ages can be affected, the incidence is higher in women.<sup>3,4</sup> UTIs can affect both outpatients and hospitalized patients, especially those with immunosuppression.<sup>2</sup> *Escherichia coli* (*E. coli*) is the predominant pathogen responsible for 80%–90% of community-acquired UTIs.<sup>5</sup> However, other bacteria, such as *Klebsiella spp.*, *Proteus spp.*, *Enterococcus spp.*, and *Staphylococcus saprophyticus* can also contribute to UTIs.<sup>3</sup>

In the United States, UTIs account for more than 10 million ambulatory visits annually.<sup>6</sup> UTIs primarily involve the invasion and proliferation of microorganisms within the urinary tract.<sup>6</sup> In Vietnam, as in most low- and middle-income countries, data on antimicrobial resistance are limited. A report from the Vietnam National Antimicrobial Resistance Surveillance Network, including the antimicrobial sensitivity testing results of bacterial isolates from clinical specimens, revealed that *E. coli* (18%) and *Klebsiella spp.* (13%), including *Klebsiella pneumoniae* (*K. pneumoniae*, 9%), are the most frequently isolated microorganisms in Vietnam.<sup>7</sup> The antimicrobial resistance levels are high in Vietnam, with more than 50% of *Enterobacteriaceae* isolates showing resistance to third-generation cephalosporins and fluoroquinolones.<sup>8</sup> However, the long-term monitoring of antimicrobial resistance in UTIs is limited.

UTIs occasionally occur without noticeable urinary symptoms, leading to delayed diagnosis and treatment.<sup>2</sup> Obtaining conclusive results from urine culture and antibiotic susceptibility testing typically takes at least 3 days.<sup>2</sup> Moreover, antibiogram testing is not routinely performed in Vietnam and other countries. For example, data extracted from a large urban healthcare system in the United States revealed that urine cultures were only ordered in 26.8% of the patients.<sup>9</sup> Hence, doctors in emergency departments face significant pressure to promptly assess the appropriateness of empirical antibiotics administered to patients with UTIs.<sup>10</sup> To assist clinicians in addressing gaps in empiric antibiotic regimens for treating UTIs and help policymakers understand the burden of UTIs in Vietnam, we analyzed the microbial profiles and antimicrobial resistance

rates in both inpatients and outpatients at a Class I hospital over 5 years.

## Methods

### Study design

This serial cross-sectional study examined the patient data over 5 years (January 2017 to December 2021) at Nghe An Friendship General Hospital, a Class I provincial hospital located in central Vietnam. This study was conducted and reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement guidelines.<sup>11</sup>

### Data collection with inclusion and exclusion criteria

The data collection process is outlined in the flowchart (Figure 1). Briefly, the information regarding UTIs was extracted from computerized medical records using a standardized data collection form. The dataset comprises various details, including demographic characteristics (age and sex), admission unit during infection, identified causative microorganisms, specimen type, and antimicrobial susceptibility testing data. The data from confirmed positive urinary cultures, including pathogen identification and antibiotic susceptibility testing, were collected. A positive culture was defined as the growth of no more than two urinary tract pathogens, with a minimum of  $1 \times 10^5$  colony-forming units per milliliter (CFU/mL) in urine specimens containing an increased white blood cell count, bacteria, proteins, or positive nitrites upon testing.<sup>12</sup> For instance, involving repetitive isolates from the same patient or contamination (i.e., the growth of three or more types of bacteria in a single specimen), and the fungal species were excluded from the study.

### Urine culture


Urine culture and subculture procedures were conducted in accordance with standard experimental guidelines established by the Department of Clinical Laboratory at Nghe An Friendship General Hospital. Briefly, urine samples were collected from patients suspected of UTIs using either midstream clean-catch or urethral catheterization. Samples were promptly delivered to the laboratory within 2 h for processing. Using a calibrated loop, 1  $\mu$ L of urine was streaked onto both



**Table 1.** The distribution of microorganisms isolated from patients with UTIs, 2017–2021.

Microorganism	Number of isolates by year (rate%)					Total
	2017	2018	2019	2020	2021	
<i>E. coli</i>	124 (45.4%)	162 (43.1%)	162 (40.7%)	182 (39.1%)	226 (45.9%)	856 (42.7%)
<i>P. aeruginosa</i>	24 (8.8%)	41 (10.9%)	61 (15.3%)	67 (14.4%)	46 (9.3%)	239 (11.9%)
<i>K. pneumoniae</i>	33 (12.1%)	44 (11.7%)	40 (10.1%)	63 (13.5%)	39 (7.9%)	219 (10.9%)
<i>E. faecium</i>	4 (1.5%)	18 (4.8%)	16 (4%)	24 (5.2%)	37 (7.5%)	99 (4.9%)
<i>E. faecalis</i>	14 (5.1%)	17 (4.5%)	31 (7.8%)	23 (4.9%)	30 (6.1%)	115 (5.7%)
<i>E. cloacae</i>	11 (4%)	22 (5.9%)	9 (2.3%)	20 (4.3%)	22 (4.5%)	84 (4.2%)
<i>P. mirabilis</i>	14 (5.1%)	9 (2.4%)	16 (4%)	12 (2.6%)	19 (3.9%)	70 (3.5%)
<i>A. baumannii</i>	10 (3.7%)	15 (4%)	18 (4.5%)	19 (4.1%)	13 (2.6%)	75 (3.7%)
Others	39 (14.3%)	48 (12.8%)	45 (11.3%)	55 (11.8%)	60 (12.2%)	247 (12.3%)
<b>Total</b>	<b>273 (100%)</b>	<b>376 (100%)</b>	<b>398 (100%)</b>	<b>465 (100%)</b>	<b>492 (100%)</b>	<b>2004 (100%)</b>

UTI, urinary tract infection.

**Figure 2.** Comparing the top three most prevalent microorganisms causing UTIs by gender, with the percentage of isolates as follows: (a) *E. coli*, (b) *K. pneumoniae*, and (c) *P. aeruginosa*.\*\* $p$ -value < 0.01.


ns, non-significance; UTI, urinary tract infection.

### Gender-associated disparities in UTI pathogen distribution

A comparison of the four predominant UTI pathogens by sex over 5 years revealed a higher prevalence of *E. coli* in women (62.3%, 531 out of 853;  $p < 0.05$ ) (Figure 2). Conversely, the prevalence of male patients infected with *Pseudomonas aeruginosa* (*P. aeruginosa*) was 76.9% (183 out of 238), which was significantly higher than that of women ( $p < 0.05$ ). Similarly, *K. pneumoniae* infection was more common in male patients than in female patients (62.1%, 136 out of 219;  $p = 0.07$ ).

### Antimicrobial resistance trends among bacterial isolates

*E. coli* and *K. pneumoniae* are the two most common enterobacterial isolates that cause UTIs. The annual rates of extended-spectrum  $\beta$ -lactamase (ESBL) positivity and antibiotic resistance among *E. coli* (Figure 3(a)) and *K. pneumoniae* (Figure 3(b)) isolates within 5 years were investigated. Although the prevalence of ESBL-producing *E. coli* was higher than that of ESBL-producing *K. pneumoniae*, a higher rate of antibiotic resistance was observed in the latter.



**Figure 3.** The antimicrobial resistance profiles of the three most prevalent UTI pathogens isolated from 2017 to 2021. This includes the annual rates of ESBL-positive strains and antibiotic resistance for (a) *E. coli*, (b) *K. pneumoniae*, and (c) *P. aeruginosa*. The red and gray dashed lines denote the cutoff points at 50% and 20% for resistant strains, respectively. UTI, urinary tract infection.



For *E. coli*, more than 50% of the isolates were identified as ESBL producers during the study period. The ESBL-positive rate peaked in 2018, accounting for approximately 79.2%, and then eventually decreased by approximately 49.4% in 2019 and 2020. The ESBL-positive rate then rose to 58.4% in 2021. Following the fluctuations in ESBL-positive rates, the resistance rates of ESBL producers against other antimicrobials showed similar trends, including those for cefoperazone and trimethoprim-sulfamethoxazole. Notably, almost all cephalosporins and fluoroquinolones exhibited a resistance rate of > 50%, as indicated by the dashed red line, which denotes the 50% threshold.

The rates of resistance to amoxicillin/clavulanic acid, gentamicin, and tobramycin fluctuated erratically, ranging from 30% to 50%. Notably, seven antimicrobial agents, including carbapenems (imipenem, ertapenem, and meropenem), aminoglycosides (amikacin), piperacillin/tazobactam, cefoperazone/sulbactam, and fosfomycin, exhibited high sensitivity to over 80%–90% of *E. coli* isolates throughout the 5-year study period (Figure 3(a)). Additionally, the resistance rates of *K. pneumoniae* isolates exceeded 50%, except for amikacin, ertapenem, imipenem, meropenem, and fosfomycin, which showed resistance rates of <50% (Figure 3(b)). Notably, the proportion of ESBL-positive *K. pneumoniae* strains fluctuated between 20% and 50%. Additionally, all *K. pneumoniae* strains isolated from patients with UTIs were resistant to ampicillin. In summary, almost all enterobacterial isolates were non-susceptible to cephalosporins, fluoroquinolones, and aminoglycosides, except for amikacin. Conversely, carbapenems, amikacin, and fosfomycin displayed the highest sensitivity among the Enterobacteriaceae isolates.

*P. aeruginosa* has emerged as the second most common bacterial pathogen in UTIs within this study. The resistance rate of *P. aeruginosa* isolates remained constantly high, ranging from 60% to 70% across the 12 different antimicrobial agents tracked throughout the study period (Figure 3(c)). Notably, the susceptibility of *P. aeruginosa* isolates to carbapenems (imipenem and meropenem) and amikacin, which typically exhibit sensitivities exceeding 80%–90% in enterobacterial isolates, was <30%.


### Changes in the antibiotic resistance rates during the coronavirus disease 2019 pandemic

The coronavirus disease 2019 (COVID-19) outbreak has presented significant challenges to all aspects of the healthcare system, including infectious disease prevention and control, diagnostics, and antibiotic usage.<sup>15</sup> The CDC has reported an increase in the incidence of hospital-acquired antibiotic-resistant infections in the United States during the pandemic.<sup>16</sup> To assess the changes in the antibiotic resistance profile of Enterobacteriaceae isolates in our hospital, we compared the proportion before and after the COVID-19 pandemic. As shown in Figure 4(a), the proportion of resistant *E. coli* following the post-COVID-19 pandemic (2020–2021) slightly decreased compared with that in the pre-COVID-19 period (2017–2019). Notably, the rates of resistance to doxycycline and tobramycin were significantly decreased. A similar downward trend was observed in the rates of *K. pneumoniae* resistance to the aforementioned antibiotics (Figure 4(b)).

### Discussion

UTI is the third most prevalent category of infection in human medicine worldwide. Our study, which included 2595 patients with UTIs, observed a nearly equal male-to-female ratio. However, the distribution of the four most prominent pathogens causing UTIs varies. *E. coli* infections were predominantly isolated from female patients, while *K. pneumoniae* and *P. aeruginosa* infections were more frequently detected in male patients. These findings suggest that women may be more susceptible to *E. coli* infections, while men may be more prone to infections caused by other opportunistic pathogens. Moreover, Malmros et al. reported 6–15 national guidelines for the empirical antibiotic treatment of UTIs that provide specific recommendations for female patients.<sup>17</sup> Therefore, the significant sex differences among UTI pathogen distributions may contribute to the development of effective treatment guidelines.

Data analysis revealed that *E. coli*, *K. pneumoniae*, and *P. aeruginosa* were the three most common bacterial pathogens isolated from patients with UTIs. This finding was consistent with those of other studies that have documented a high risk of



**Figure 4.** Antimicrobial resistance patterns of *E. coli* and *K. pneumoniae* isolates from UTIs spanning 2017 to 2021 are depicted. The bar graph showcases the prevalence of ESBL-positive strains and their resistance profiles to various antimicrobial agents for both (a) *E. coli* and (b) *K. pneumoniae* isolates. A comparison is drawn between surveillance before (2017–2019) and after (2020–2021) the COVID-19 pandemic. The dashed lines denote the cutoff points at 20% (blue) and 50% (red) for resistant strains. UTI, urinary tract infection.

UTI associated with these pathogens.<sup>10,18</sup> In the present study, most *E. coli* strains were resistant to commonly prescribed antibiotics such as ampicillin, cephalosporin, and fluoroquinolone (>50% threshold). Notably, *E. coli* isolates displayed high

susceptibility, with rates ranging from 80% to 90%, to seven antimicrobial drugs analyzed in the study, including three carbapenems (imipenem, ertapenem, and meropenem), amikacin, piperacillin/tazobactam, cefoperazone/sulbactam, and

fosfomycin. Consistent with several national guidelines, fosfomycin is highly recommended as a first-line treatment for UTIs.<sup>12,17,19</sup> By contrast, *K. pneumoniae* exhibited high-resistance rates across all classes of antibiotics, with most antibiotics showing resistance rates exceeding 50%. Only five antibiotics (amikacin, ertapenem, imipenem, meropenem, and fosfomycin) exhibited < 50% resistance rates during the study period. Previous and more recent studies have shown that enterobacterial isolates are highly sensitive to amikacin, imipenem, and meropenem,<sup>20–22</sup> suggesting that these antibiotics can serve as effective treatment options for UTIs caused by Enterobacteriaceae. Besides, ampicillin has been suggested in numerous national guidelines for pregnant patients owing to its safety.<sup>12,17</sup> However, our antibiotic profile of enterobacterial UTIs indicated that ampicillin is not effective for the treatment of enterobacterial UTIs in our country.

Meanwhile, the sensitivity of *P. aeruginosa* UTIs to carbapenems and amikacin was significantly low, falling below 30%. Of particular concern is the limited susceptibility of *P. aeruginosa* isolates to carbapenems (imipenem and meropenem) and amikacin, which are crucial therapeutic agents for the treatment of multidrug-resistant infections. This result underscores the need for developing alternative treatment strategies and personalized testing to address multidrug resistance.

The increasing prevalence of ESBL-producing bacteria is a global concern. In our study, the prevalence of ESBL-producing *E. coli* was relatively high, and more than half of the isolates exhibited ESBL activity. Conversely, the prevalence of ESBL-producing *K. pneumoniae* fluctuated between 20% and 50%. In previous studies, the proportions of ESBL-producing *E. coli* and *K. pneumoniae* isolated from urine were approximately 48%–65%<sup>23,24</sup> and 37.0%–44.0%,<sup>25,26</sup> respectively. Consistent with the findings of other studies conducted in Vietnam, the prevalence of ESBL producers was approximately 50%.<sup>27</sup> The acquisition of ESBLs renders these bacteria resistant to several commonly used antibiotics.<sup>20,28</sup> The molecular characteristics of  $\beta$ -lactamases, including ESBL, AmpC  $\beta$ -lactamases, and carbapenemases, among Enterobacteriaceae have been previously reported to be highly prevalent in Vietnam.<sup>27,29</sup> Since the use of ESBL detection data from automated systems has limitations in

identifying these enzymes,<sup>30</sup> further studies on the phenotypic and genotypic distribution of ESBL, AmpC  $\beta$ -lactamase and carbapenemase-producing Enterobacteriaceae would help elucidate the detailed mechanisms of antimicrobial resistance.

Globally, our results on antimicrobial resistance address a significant data gap by identifying urgent trends in UTI resistance. These findings provide essential surveillance data on antibiotic resistance profiles, helping to prioritize the development of new antibiotics for high-resistance pathogens, redirect research focus, and shape global treatment guidelines, particularly for countries facing similar resistance challenges. This approach ensures that empirical therapies remain effective, even in regions with limited local data.

Additionally, during the COVID-19 pandemic, several factors, such as hand hygiene, mask usage, social distancing, and the widespread dissemination of infection prevention and control guidelines,<sup>31,32</sup> may have contributed to the occurrence of antibiotic resistance. When comparing the periods before and after the COVID-19 outbreak, a declining trend was observed in the antibiotic resistance rates of *E. coli* and *K. pneumoniae*. This trend aligns with the report of recent studies, which indicated a significant reduction in antimicrobial resistance during the pandemic.<sup>33</sup> However, various studies yielded conflicting findings regarding the correlation between COVID-19 and antimicrobial drug resistance. Although some studies have suggested a non-statistically significant increase,<sup>34,35</sup> others have observed an increase in the prevalence of multidrug-resistant infections during the pandemic.<sup>36–38</sup> These results highlight the importance of implementing effective infection prevention and control guidelines as an additional strategy to manage antibiotic-resistant UTIs.

This study has several limitations. The retrospective study design introduced inherent biases, as data on the severity of illness and duration of hospital stay for these isolates were not collected. The sample size was based on all available UTI samples from both inpatient and outpatient cases during the study period. Additionally, this study lacked access to individual patient records, limiting the ability to evaluate correlations with clinically relevant risk factors. Further investigations, incorporating a broader range of diagnostic



methods and larger sample sizes, may provide a more comprehensive understanding of the microbial landscape of UTIs.

## Conclusion

This study investigated the epidemiology and antimicrobial patterns of UTIs in Vietnam in recent years. Two-thirds of UTI cases were caused by enterobacterial pathogens, including *E. coli* and *K. pneumoniae*, which exhibit high rates of antibiotic resistance. Amikacin, ertapenem, imipenem, meropenem, and fosfomycin are promising treatment options for UTIs caused by Enterobacteriaceae. However, their effectiveness against *P. aeruginosa*, which accounts for 11.9% of all UTI cases, is limited. These findings underscore the importance of optimizing national guidelines and implementing personalized treatment strategies to effectively manage UTIs amidst the increasing prevalence of antimicrobial resistance.

## Declarations

### *Ethics approval and consent to participate*

This study was conducted as an internal audit, using only anonymized data to ensure participant confidentiality. Data collection and analysis adhered strictly to ethical guidelines for research involving human subjects. Prior to the commencement of the study, approval was obtained from the Human Ethics Committee of Health Research at Nghe An Friendship General Hospital (Approval No: BVHNNA230610). Since no identifiable personal data was collected, the requirement for informed consent was waived by the ethics committee.

### *Consent for publication*

Not applicable.

### *Author contributions*

**Anh Tram Que:** Conceptualization; Data curation; Investigation; Methodology; Project administration; Resources; Software; Validation; Writing – review & editing.

**Anh Dao Tran:** Conceptualization; Data curation; Investigation; Methodology; Resources; Software; Validation; Writing – review & editing.

**Thi Hong Nhung Trang:** Conceptualization; Validation; Visualization; Writing – review & editing.

**Thi Nhu Le Tran:** Conceptualization; Validation; Visualization; Writing – review & editing.

**Ngoc-Niem Bui:** Conceptualization; Formal analysis; Validation; Visualization; Writing – original draft; Writing – review & editing.

**Chih-Ho Lai:** Conceptualization; Funding acquisition; Methodology; Supervision; Validation; Writing – review & editing.

### *Acknowledgements*

The authors thank the editor and the reviewers for their editorial assistance and valuable comments. The authors gratefully acknowledge the support from Nghe An Friendship General Hospital, Tra Vinh University, and Can Tho University of Medicine and Pharmacy, Vietnam.

### *Funding*

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the National Science and Technology Council (112-2320-B-182-036-MY3 and 112-2320-B-182-042-MY3), Chang Gung Memorial Hospital (CMRPD1K0361, CMRPD1L0321, CMRPD1M0491-2, and CORPD1M0021-3), Research Center for Emerging Viral Infections from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Taiwan Ministry of Education, and Tomorrow Medical Foundation.

### *Competing interests*

The authors declare that there is no conflict of interest.

### *Availability of data and materials*

The datasets produced and analyzed in this study are available from the corresponding author upon reasonable request.

### **ORCID iDs**

Anh Dao Tran  <https://orcid.org/0009-0007-5434-6276>

Thi Nhu Le Tran  <https://orcid.org/0000-0002-5990-8967>

Ngoc-Niem Bui  <https://orcid.org/0000-0003-0928-791X>

Chih-Ho Lai  <https://orcid.org/0000-0001-7145-784X>

## Supplemental material

Supplemental material for this article is available online.

## References

- Gajdacs M, Abrok M, Lazar A, et al. Increasing relevance of Gram-positive cocci in urinary tract infections: a 10-year analysis of their prevalence and resistance trends. *Sci Rep* 2020; 10: 17658.
- Wilson ML and Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. *Clin Infect Dis* 2004; 38: 1150–1158.
- Gnimatin JP, Weyori EW, Agossou SM, et al. Bacterial infections epidemiology and factors associated with multidrug resistance in the northern region of Ghana. *Sci Rep* 2022; 12: 22069.
- Bruxvoort KJ, Bider-Canfield Z, Casey JA, et al. Outpatient urinary tract infections in an era of virtual healthcare: trends from 2008 to 2017. *Clin Infect Dis* 2020; 71: 100–108.
- Ganguanco LM, Alejandria M, Henson KE, et al. Prevalence and risk factors for trimethoprim-sulfamethoxazole-resistant *Escherichia coli* among women with acute uncomplicated urinary tract infection in a developing country. *Int J Infect Dis* 2015; 34: 55–60.
- Maddali N, Cantin A, Koshy S, et al. Antibiotic prescribing patterns for adult urinary tract infections within emergency department and urgent care settings. *Am J Emerg Med* 2021; 45: 464–471.
- Vu TVD, Choisy M, Do TTN, et al. Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016–2017. *Antimicrob Resist Infect Control* 2021; 10: 78.
- Phu DH, Wongtawan T, Truong DB, et al. A systematic review and meta-analysis of integrated studies on antimicrobial resistance in Vietnam, with a focus on *Enterobacteriaceae*, from a One Health perspective. *One Health* 2022; 15: 100465.
- Kon S, Meslovich D, Valdez C, et al. Long-term impact of fluoroquinolone-sparing strategies for empirical treatment of acute uncomplicated cystitis among ambulatory patients. *Ther Adv Infect Dis* 2022; 9: 20499361221129415.
- Dunne MW, Puttagunta S, Aronin SI, et al. Impact of empirical antibiotic therapy on outcomes of outpatient urinary tract infection due to nonsusceptible *Enterobacterales*. *Microbiol Spectr* 2022; 10: e0235921.
- Uhlig K, Menon V and Schmid CH. Recommendations for reporting of clinical research studies. *Am J Kidney Dis* 2007; 49: 3–7.
- Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2019; 68: e83–e110.
- Price TK, Dune T, Hilt EE, et al. The clinical urine culture: enhanced techniques improve detection of clinically relevant microorganisms. *J Clin Microbiol* 2016; 54: 1216–1222.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. CLSI supplement M100. In: Clinical and Laboratory Standards Institute 2017–2021; 27th–31st ed.
- Blumenthal D, Fowler EJ, Abrams M, et al. Covid-19 – implications for the Health Care System. *N Engl J Med* 2020; 383: 1483–1488.
- COVID-19: U.S. impact on antimicrobial resistance, special report 2022. Special report. Atlanta, GA: U.S. Department of Health and Human Services: US Centers for Disease Control and Prevention 2022.
- Malmros K, Huttner BD, McNulty C, et al. Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries: results of an online survey. *Int J Antimicrob Agents* 2019; 54: 478–486.
- Carlotta N, Nitin M, Dave B, et al. Gram negative bacteria related urinary tract infections: spectrum of antimicrobial resistance over 9 years in a University tertiary referral Hospital. *Ther Adv Infect Dis* 2024; 11: 20499361241228342.
- Bielen L and Likic R. Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing *Enterobacteriaceae*. *Ther Adv Infect Dis* 2019; 6: 2049936119858883.
- Gharavi MJ, Zarei J, Roshani-Asl P, et al. Comprehensive study of antimicrobial susceptibility pattern and extended spectrum beta-lactamase (ESBL) prevalence in bacteria isolated from urine samples. *Sci Rep* 2021; 11: 578.
- Wanke-Rytt M, Sobierajski T, Lachowicz D, et al. Analysis of etiology of community-Acquired and nosocomial urinary tract infections and antibiotic resistance of isolated strains: results of a 3-year surveillance (2020–2022) at the pediatric teaching hospital in Warsaw. *Microorganisms* 2023; 11: 1438.
- Wang JL, Lai CC, Tsai YW, et al. Global trends in nonsusceptibility rates of *Escherichia coli* isolates to meropenem and ceftazidime/avibactam: data from the antimicrobial

- testing leadership and Surveillance (ATLAS) programme, 2014–21. *Int J Antimicrob Agents* 2024; 63: 107103.
23. FarajzadehSheikh A, Veisi H, Shahin M, et al. Frequency of quinolone resistance genes among extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* strains isolated from urinary tract infections. *Trop Med Health* 2019; 47: 19.
  24. Ehsan B, Haque A, Qasim M, et al. High prevalence of extensively drug resistant and extended spectrum beta lactamases (ESBLs) producing uropathogenic *Escherichia coli* isolated from Faisalabad, Pakistan. *World J Microbiol Biotechnol* 2023; 39: 132.
  25. Fils PEL, Cholley P, Gbaguidi-Haore H, et al. ESBL-producing *Klebsiella pneumoniae* in a University hospital: molecular features, diffusion of epidemic clones and evaluation of cross-transmission. *PLoS One* 2021; 16: e0247875.
  26. Siriphap A, Kittit T, Khuekankaew A, et al. High prevalence of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolates: a 5-year retrospective study at a Tertiary Hospital in Northern Thailand. *Front Cell Infect Microbiol* 2022; 12: 955774.
  27. Jean SS, Hsueh PR and Group SA-P. Distribution of ESBLs, AmpC beta-lactamases and carbapenemases among *Enterobacteriaceae* isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008–14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). *J Antimicrob Chemother* 2017; 72: 166–171.
  28. Huang PY, Hsu CK, Liu TH, et al. Clinical efficacy of ertapenem vs. other carbapenems for the treatment of extended-spectrum-beta-lactamase-producing *Enterobacteriales* infection: a systematic review and meta-analysis. *J Glob Antimicrob Resist* 2023; 33: 201–207.
  29. Chen YC, Chen WY, Hsu WY, et al. Distribution of beta-lactamases and emergence of carbapenemases co-occurring *Enterobacteriales* isolates with high-level antibiotic resistance identified from patients with intra-abdominal infection in the Asia-Pacific region, 2015–2018. *J Microbiol Immunol Infect* 2022; 55: 1263–1272.
  30. El-Jade MR, Parcina M, Schmithausen RM, et al. ESBL detection: comparison of a commercially available chromogenic test for third generation cephalosporine resistance and automated susceptibility testing in enterobacteriaceae. *PLoS One* 2016; 11: e0160203.
  31. Chiu NC, Chi H, Tai YL, et al. Impact of wearing masks, hand hygiene, and social distancing on influenza, enterovirus, and all-cause pneumonia during the coronavirus pandemic: retrospective national epidemiological surveillance study. *J Med Internet Res* 2020; 22: e21257.
  32. Lo SH, Lin CY, Hung CT, et al. The impact of universal face masking and enhanced hand hygiene for COVID-19 disease prevention on the incidence of hospital-acquired infections in a Taiwanese hospital. *Int J Infect Dis* 2021; 104: 15–18.
  33. Bauer KA, Puzniak LA, Yu KC, et al. A multicenter comparison of prevalence and predictors of antimicrobial resistance in hospitalized patients before and during the severe acute respiratory syndrome coronavirus 2 pandemic. *Open Forum Infect Dis* 2022; 9: ofac537.
  34. Langford BJ, Soucy JR, Leung V, et al. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. *Clin Microbiol Infect* 2023; 29: 302–309.
  35. Venugopal S, Chunchanur S, Panigrahy R, et al. Changes in antimicrobial resistance of *Escherichia coli* isolated from community associated urinary tract infection before and during the COVID-19 pandemic in India. *J Glob Antimicrob Resist* 2024; 37:165–167.
  36. Khoshbakht R, Kabiri M, Neshani A, et al. Assessment of antibiotic resistance changes during the COVID-19 pandemic in northeast of Iran during 2020–2022: an epidemiological study. *Antimicrob Resist Infect Control* 2022; 11: 121.
  37. Mutua J, Musyoki A and Mwaniki J. High rate of multidrug resistant bacterial infections in critically ill COVID-19 patients admitted at the peak of pandemic in a national referral hospital, Kenya. *Int J Infect Dis* 2023; 130: S25.
  38. Amodio E, Pizzo S, Vella G, et al. Increase of multidrug-resistant bacteria after the COVID-19 pandemic in a major teaching Hospital in Sicily (2018–2021). *Int J Antimicrob Agents* 2024; 63: 107123.